Everest Returns Greater China Rights for Trodelvy to Gilead for $455 Million

Shanghai Everest Medicines (returned rights for Trodelvy® (sacituzumab govitecan) to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million. In 2009, Everest acquired rights to the Trop-2 ADC candidate in a $835 million deal ($65 million upfront). Two months ago, Everest was approved to launch Trodelvy in China as a third-line therapy for metastatic triple-negative breast cancer (TNBC). Everest will receive $280 million in upfront payments and up to $175 million in future milestones. The company will be released from paying $710 million in remaining milestones under the Immunomedics deal, indicating Everest has paid $155 million to Immunomedics/Gilead to date. More details....

Stock Symbols: HK: 1952) (NSDA: GILD)

Share this with colleagues: